Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + Grafting for Resistant Vitiligo
NCT05872477Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib cream in nonsegmental vitiligo (NSV), sponsored by Centre Hospitalier Universitaire de Nice. Started Sep 2023; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT05872477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872477.